## SENATE BILL No. 238

By Committee on Judiciary

2-10

AN ACT concerning crimes, punishment and criminal procedure; relating to crimes involving controlled substances; adding the placing of controlled substances into pills into the definition of manufacture; increasing the criminal penalties for manufacturing or distributing fentanyl-related controlled substances; creating a special sentencing rule for manufacturing or distributing fentanyl-related controlled substances and any controlled substances that are likely to be attractive to minors because of their appearance or packaging; amending K.S.A. 2022 Supp. 21-5701, 21-5703, 21-5705 and 21-6805 and repealing the existing sections; also repealing K.S.A. 2022 Supp. 21-5701b.

1 2

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2022 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2022 Supp. 21-5701 through 21-5717, and amendments thereto:

- (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto:
- (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
  - (2) "Controlled substance analog" does not include:

(A) A controlled substance;

- (B) a substance for which there is an approved new drug application; or
  - (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
  - (c) "Cultivate" means the planting or promotion of growth of five or more plants that contain or can produce controlled substances.
  - (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
    - (e) (1) "Drug" means:
- (A) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;
- (B) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or animals;
- (C) substances, other than food, intended to affect the structure or any function of the body of humans or animals; and
- (D) substances intended for use as a component of any article specified in subparagraph (A), (B) or (C).
- (2) "Drug" does not include devices or their components, parts or accessories.
- (f) (1) "Drug paraphernalia" means all equipment and materials of any kind that are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:
- $\frac{(1)}{A}$  Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant that is a controlled substance or from which a controlled substance can be derived;
- (2)(B) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
  - (3)(C) isomerization devices used or intended for use in increasing

the potency of any species of plant that is a controlled substance;

- (4)(D) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
- (5)(E) scales and balances used or intended for use in weighing or measuring controlled substances;
- (6)(F) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose that are used or intended for use in cutting controlled substances;
- (7)(G) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
- $\frac{(8)}{(H)}$  blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
- (9)(I) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
- $\frac{(10)}{J}$  containers and other objects used or intended for use in storing or concealing controlled substances;
- $\frac{(11)}{(K)}$  hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
- $\frac{(12)}{L}$  objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
- (A)(i) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
- (B)(ii) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
  - (C)(iii) carburetion pipes, glass or other-heat resistant heat-resistant tubes or any other device used, intended to be used or designed to be used to cause vaporization of a controlled substance for inhalation;
    - (D)(iv) smoking and carburetion masks;
- $\frac{(E)}{(v)}$  roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand:
- (F)(vi) miniature cocaine spoons and cocaine vials;
- 38 (G)(vii) chamber smoking pipes;
- 39 (H)(viii) carburetor smoking pipes;
- (H)(ix) electric smoking pipes;
- (J)(x) air-driven smoking pipes;
- $\frac{(K)}{(xi)}$  chillums;
- (L)(xii) bongs;

(M)(xiii) ice pipes or chillers;

- (N)(xiv) any smoking pipe manufactured to disguise its intended purpose;
  - $(\Theta)(xv)$  wired cigarette papers; or
  - (P)(xvi) cocaine freebase kits.
- (2) "Drug paraphernalia"—shall does not include any products, chemicals or materials described in K.S.A. 2022 Supp. 21-5709(a), and amendments thereto.
- (g) "Fentanyl-related controlled substance" means any substance designated in K.S.A. 65-4105(b)(1), (b)(2), (b)(4), (b)(10), (b)(11), (b)(14), (b)(15), (b)(16), (b)(20), (b)(22), (b)(23), (b)(24), (b)(37), (b)(41), (b)(45), (b)(46), (b)(47), (b)(49), (b)(57), (b)(58), (b)(59), (b)(60), (b)(61), (b)(62), (b)(73), (b)(74), (b)(78), (g)(1) or (g)(2) or 65-4107(c)(1), (c)(6), (c)(9), (c)(26), (c)(28), (c)(30), (f)(3)(A) or (f)(3)(B), and amendments thereto, or any analog thereof.
- (h) "Immediate precursor" means a substance that the state board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
  - (h)(i) "Isomer" means all enantiomers and diastereomers.
- (i)(j) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of *or placing into pill or capsule form* a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
- (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are intended for use in cutting a controlled substance.
  - (j)(k) "Marijuana" means all parts of all varieties of the plant

1 2

 Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include:

- (1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is incapable of germination;
- 10 (2) any substance listed in schedules II through V of the uniform controlled substances act;
  - (3) drug products approved by the United States food and drug administration as of the effective date of this act;
  - (4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or
  - (5) industrial hemp as defined in K.S.A. 2-3901, and amendments thereto, when cultivated, produced, possessed or used for activities authorized by the commercial industrial hemp act.
    - (k)(l) "Minor" means a person under 18 years of age.
  - (h)(m) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
  - (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
  - (2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
    - (3) opium poppy and poppy straw;
  - (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.
  - (m)(n) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.
  - (n)(o) "Opium poppy" means the plant of the species Papaver

somniferum l. except its seeds.

- (o)(p) "Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- $\frac{(p)}{(q)}$  "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.
- (s) "Simulated controlled substance" means any product that identifies itself by a common name or slang term associated with a controlled substance and that indicates on its label or accompanying promotional material that the product simulates the effect of a controlled substance.
- Sec. 2. K.S.A. 2022 Supp. 21-5703 is hereby amended to read as follows: 21-5703. (a) It shall be unlawful for any person to manufacture any controlled substance or controlled substance analog.
  - (b) Violation or attempted violation of subsection (a) is a:
- (1) Drug severity level 2 felony, except as provided in subsections (b) (2) and (b)(3);
  - (2) drug severity level 1 felony if:
- (A) The controlled substance is not methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof; and
- (B) the controlled substance is not a fentanyl-related controlled substance; and
- (C) the offender has a prior conviction for unlawful manufacturing of a controlled substance under this section, K.S.A. 65-4159, prior to its repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, or a substantially similar offense from another jurisdiction and the substance was not methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-

 4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, in any such prior conviction; and

- (3) drug severity level 1 felony if the controlled substance is methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, or is a fentanyl-related controlled substance.
- (c) The provisions of subsection (d) of K.S.A. 2022 Supp. 21-5301(d), and amendments thereto, shall not apply to a violation of attempting to unlawfully manufacture any controlled substance or controlled substance analog pursuant to this section.
- (d) For persons arrested and charged under this section, bail shall be at least \$50,000 cash or surety, and such person shall not be released upon the person's own recognizance pursuant to K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the defendant is not likely to re-offend, the court imposes pretrial supervision, or the defendant agrees to participate in a licensed or certified drug treatment program.
- (e) The sentence of a person who violates this section shall not be subject to statutory provisions for suspended sentence, community service work or probation.
- (f) The sentence of a person who violates this section, K.S.A. 65-4159, prior to its repeal or K.S.A. 2010 Supp. 21-36a03, prior to its transfer, shall not be reduced because these sections prohibit conduct identical to that prohibited by K.S.A. 65-4161 or 65-4163, prior to their repeal, K.S.A. 2010 Supp. 21-36a05, prior to its transfer, or K.S.A. 2022 Supp. 21-5705, and amendments thereto.
- Sec. 3. K.S.A. 2022 Supp. 21-5705 is hereby amended to read as follows: 21-5705. (a) It shall be unlawful for any person to distribute or possess with the intent to distribute any of the following controlled substances or controlled substance analogs thereof:
- (1) Opiates, opium or narcotic drugs, or any stimulant designated in subsection (d)(1), (d)(3) or (f)(1) of K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), and amendments thereto;
- (2) any depressant designated in subsection (e) of K.S.A. 65-4105(e), subsection (e) of K.S.A. 65-4107(e), subsection (b) or (e) of K.S.A. 65-4109(b) or (c) or subsection (b) of K.S.A. 65-4111(b), and amendments thereto;
- (3) any stimulant designated in subsection (f) of K.S.A. 65-4105(f), subsection (d)(2), (d)(4), (d)(5) or (f)(2) of K.S.A. 65-4107(d)(2), (d)(4), (d)(5) or (f)(2) or subsection (e) of K.S.A. 65-4109(e), and amendments thereto:
- 42 (4) any hallucinogenic drug designated in—subsection (d) of K.S.A. 43 65-4105(d),—subsection (g) of K.S.A. 65-4107(g) or—subsection (g) of

SB 238 8

1

2

3 4

5

6

7

8

9

10

11 12

13

14 15

16

17

18 19

20

21

22

23

24

25

26

27 28

29

30 31

32

33

34

35

36 37

38

41

43

K.S.A. 65-4109(g), and amendments thereto:

- (5) any substance designated in subsection (g) of K.S.A. 65-4105(g) and subsection (e), (d), (e), (f) or (g) of K.S.A. 65-4111(c), (d), (e), (f) or (g), and amendments thereto;
- (6) any anabolic steroids as defined in subsection (f) of K.S.A. 65-4109(f), and amendments thereto; or
- (7) any substance designated in-subsection (h) of K.S.A. 65-4105(h), and amendments thereto.
- (b) It shall be unlawful for any person to distribute or possess with the intent to distribute a controlled substance or a controlled substance analog designated in K.S.A. 65-4113, and amendments thereto.
- (c) It shall be unlawful for any person to cultivate any controlled substance or controlled substance analog listed in subsection (a).
  - (d) (1) Except as provided further, violation of subsection (a) is a:
- (A) Drug severity level 4 felony if the quantity of the material was less than 3.5 grams;
- (B) drug severity level 3 felony if the quantity of the material was at least 3.5 grams but less than 100 grams;
- (C) drug severity level 2 felony if the quantity of the material was at least 100 grams but less than 1 kilogram; and
- (D) drug severity level 1 felony if the quantity of the material was 1 kilogram or more.
- (2) Violation of subsection (a) with respect to material containing any quantity of marijuana, or an analog thereof, is a:
- (A) Drug severity level 4 felony if the quantity of the material was less than 25 grams:
- (B) drug severity level 3 felony if the quantity of the material was at least 25 grams but less than 450 grams;
- (C) drug severity level 2 felony if the quantity of the material was at least 450 grams but less than 30 kilograms; and
- (D) drug severity level 1 felony if the quantity of the material was 30 kilograms or more.
- (3) Violation of subsection (a) with respect to material containing any quantity of heroin, as defined by subsection (e)(1) of K.S.A. 65-4105(c) (1), and amendments thereto, or methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or a fentanyl-related controlled substance or an analog thereof, is a:
- 39 (A) Drug severity level 4 felony if the quantity of the material was 40 less than 1 gram;
- (B) drug severity level 3 felony if the quantity of the material was at least 1 gram but less than 3.5 grams; 42
  - (C) drug severity level 2 felony if the quantity of the material was at

SB 238 9

1

2

3

4

5 6

7

8

9

10

11

12

13 14

15

16

17

18 19

20

23

24 25

26

27 28

29

31

32

33

34

35

36 37

38

41

42

43

least 3.5 grams but less than 100 grams; and

- (D) drug severity level 1 felony if the quantity of the material was 100 grams or more.
- (4) Violation of subsection (a) with respect to material containing any quantity of a controlled substance designated in K.S.A. 65-4105, 65-4107, 65-4109 or 65-4111, and amendments thereto, or an analog thereof, distributed by dosage unit, is a:
- (A) Drug severity level 4 felony if the number of dosage units was fewer than 10;
- (B) drug severity level 3 felony if the number of dosage units was at least 10 but less than 100:
  - (C) drug severity level 2 felony if the number of dosage units was at least 100 but less than 1,000; and
  - (D) drug severity level 1 felony if the number of dosage units was 1.000 or more.
  - (5) For any violation of subsection (a), the severity level of the offense shall be increased one level if the controlled substance or controlled substance analog was distributed or possessed with the intent to distribute on or within 1,000 feet of any school property.
    - (6) Violation of subsection (b) is a:
- 21 (A) Class A person misdemeanor, except as provided in subsection 22 (d)(6)(B); and
  - (B) nondrug severity level 7, person felony if the substance was distributed to or possessed with the intent to distribute to a minor.
    - (7) Violation of subsection (c) is a:
  - (A) Drug severity level 3 felony if the number of plants cultivated was more than 4 but fewer than 50;
  - (B) drug severity level 2 felony if the number of plants cultivated was at least 50 but fewer than 100; and
- (C) drug severity level 1 felony if the number of plants cultivated was 30 100 or more.
  - (e) In any prosecution under this section, there shall be a rebuttable presumption of an intent to distribute if any person possesses the following quantities of controlled substances or analogs thereof:
    - (1) 450 grams or more of marijuana;
    - (2) 3.5 grams or more of heroin or methamphetamine;
    - (3) 100 dosage units or more containing a controlled substance; or
    - (4) 100 grams or more of any other controlled substance.
- 39 (f) It shall not be a defense to charges arising under this section that 40 the defendant:
  - (1) Was acting in an agency relationship on behalf of any other party in a transaction involving a controlled substance or controlled substance analog;

(2) did not know the quantity of the controlled substance or controlled substance analog; or

- (3) did not know the specific controlled substance or controlled substance analog contained in the material that was distributed or possessed with the intent to distribute.
  - (g) As used in this section:

- (1) "Material" means the total amount of any substance, including a compound or a mixture, which contains any quantity of a controlled substance or controlled substance analog.
- (2) "Dosage unit" means a controlled substance or controlled substance analog distributed or possessed with the intent to distribute as a discrete unit, including but not limited to, one pill, one capsule or one microdot, and not distributed by weight.
- (A) For steroids, or controlled substances in liquid solution legally manufactured for prescription use, or an analog thereof, "dosage unit" means the smallest medically approved dosage unit, as determined by the label, materials provided by the manufacturer, a prescribing authority, licensed health care professional or other qualified health authority.
- (B) For illegally manufactured controlled substances in liquid solution, or controlled substances in liquid products not intended for ingestion by human beings, or an analog thereof, "dosage unit" means 10 milligrams, including the liquid carrier medium, except as provided in subsection (g)(2)(C).
- (C) For lysergic acid diethylamide (LSD) in liquid form, or an analog thereof, a dosage unit is defined as 0.4 milligrams, including the liquid medium.
- Sec. 4. K.S.A. 2022 Supp. 21-6805 is hereby amended to read as follows: 21-6805. (a) The provisions of this section shall be applicable to the sentencing guidelines grid for drug crimes. The following sentencing guidelines grid for drug crimes shall be applicable to felony crimes under K.S.A. 2022 Supp. 21-5701 through 21-5717, and amendments thereto, except as otherwise provided by law:

1

## SENTENCING RANGE - DRUG OFFENSES

I	1 Misdemeanor No Record	146 138	98	49		11 10
	Misd	154	103	51		12
1	2+ Misdemeanors	0 142	96	49		12
Н	2+ Misdeme	161 150	108	54 51		14 13
	rson	146	66	51		14
G	1 Nonperson Felony	162 154	110 104	57 54		16 15
	son	150	101	25		16
ŢH	2 Nonperson Felonies	167 158	113 108	59 56		18 17
	on	154	105	55		18
团	3 + Nonperson Felonies	162	111	59		20
		170	111	60	32	
D	1 Person Felony	170	117	64	3.4	
	Pe	179	124	89	36	
	on & erson ies	169	117	65	37	
Ü	1 Person & 1 Nonperson Felonies	187 178	130 123	72 68	42 40	
	d 8	176	122	89	41	32
В	2 Person Felonies	186	130	73	44	34
		196	137	77	47	36
A	3 + Person Felonies	194	136	78	49	40
	Pe	204	144	83	51	42
Category →	Severity Level	Ι	II	III	IV	Λ

(b) Sentences expressed in the sentencing guidelines grid for drug crimes in subsection (a) represent months of imprisonment.

- (c) (1) The sentencing court has discretion to sentence at any place within the sentencing range. In the usual case it is recommended that the sentencing judge select the center of the range and reserve the upper and lower limits for aggravating and mitigating factors insufficient to warrant a departure. The sentencing court shall not distinguish between the controlled substances cocaine base (9041L000) and cocaine hydrochloride (9041L005) when sentencing within the sentencing range of the grid block.
- (2) In presumptive imprisonment cases, the sentencing court shall pronounce the complete sentence which shall include the:
  - (A) Prison sentence;
- (B) maximum potential reduction to such sentence as a result of good time; and
- (C) period of postrelease supervision at the sentencing hearing. Failure to pronounce the period of postrelease supervision shall not negate the existence of such period of postrelease supervision.
- (3) In presumptive nonprison cases, the sentencing court shall pronounce the prison sentence as well as the duration of the nonprison sanction at the sentencing hearing.
- (d) Each grid block states the presumptive sentencing range for an offender whose crime of conviction and criminal history place such offender in that grid block. If an offense is classified in a grid block below the dispositional line, the presumptive disposition shall be nonimprisonment. If an offense is classified in a grid block above the dispositional line, the presumptive disposition shall be imprisonment. If an offense is classified in grid blocks 4-E, 4-F, 4-G, 4-H, 4-I, 5-C or 5-D, the court may impose an optional nonprison sentence as provided in subsection (q) of K.S.A. 2022 Supp. 21-6804(q), and amendments thereto.
- (e) The sentence for a second or subsequent conviction for unlawful manufacturing of a controlled substance, K.S.A. 65-4159, prior to its repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, K.S.A. 2022 Supp. 21-5703, and amendments thereto, or a substantially similar offense from another jurisdiction, if the controlled substance in any prior conviction was methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, shall be a presumptive term of imprisonment of two times the maximum duration of the presumptive term of imprisonment. The court may impose an optional reduction in such sentence of not to exceed 50% of the mandatory increase provided by this subsection upon making a finding on the record that one or more of the mitigating factors as specified in K.S.A. 2022 Supp. 21-6815, and amendments thereto, justify such a

1

2

3

4

5

6

7

8

9 10

11

12

13 14

15 16

17 18

19

20

21

22

23

24

25

26

2728

29

30

31

32

33

34

35

36

37

38

39

40

41

42 43 reduction in sentence. Any decision made by the court regarding the reduction in such sentence shall not be considered a departure and shall not be subject to appeal.

- (f) (1) The sentence for a third or subsequent felony conviction of K.S.A. 65-4160 or 65-4162, prior to their repeal, K.S.A. 2010 Supp. 21-36a06, prior to its transfer, or K.S.A. 2022 Supp. 21-5706, and amendments thereto, shall be a presumptive term of imprisonment and the defendant shall be sentenced to prison as provided by this section. The defendant's term of imprisonment shall be served in the custody of the secretary of corrections in a facility designated by the secretary. Subject to appropriations therefore, the defendant shall participate in an intensive substance abuse treatment program, of at least four months duration, selected by the secretary of corrections. If the secretary determines that substance abuse treatment resources are otherwise available, such term of imprisonment may be served in a facility designated by the secretary of corrections in the custody of the secretary of corrections to participate in an intensive substance abuse treatment program. The secretary's determination regarding the availability of treatment resources shall not be subject to review. Upon the successful completion of such intensive treatment program, the offender shall be returned to the court and the court may modify the sentence by directing that a less severe penalty be imposed in lieu of that originally adjudged. If the offender's term of imprisonment expires, the offender shall be placed under the applicable period of postrelease supervision.
- (2) Such defendant's term of imprisonment shall not be subject to modification under paragraph (1) if:
- (A) The defendant has previously completed a certified drug abuse treatment program, as provided in K.S.A. 75-52,144, and amendments thereto;
- (B) has been discharged or refused to participate in a certified drug abuse treatment program, as provided in K.S.A. 75-52,144, and amendments thereto;
- (C) has completed an intensive substance abuse treatment program under paragraph (1); or
- (D) has been discharged or refused to participate in an intensive substance abuse treatment program under paragraph (1).

The sentence under this subsection shall not be considered a departure and shall not be subject to appeal.

(g) (1) Except as provided further, if the trier of fact makes a finding that an offender carried a firearm to commit a drug felony, or in furtherance of a drug felony, possessed a firearm, in addition to the sentence imposed pursuant to K.S.A. 2022 Supp. 21-6801 through 21-6824, and amendments thereto, the offender shall be sentenced to:

1 2

3

4 5

6

7

8

9

10

11 12

13 14

- (A) Except as provided in subsection (g)(1)(B), an additional 6 months' imprisonment; and
- (B) if the trier of fact makes a finding that the firearm was discharged, an additional 18 months' imprisonment.
- (2) The sentence imposed pursuant to subsection (g)(1) shall be presumptive imprisonment. Such sentence shall not be considered a departure and shall not be subject to appeal.
- (3) The provisions of this subsection shall not apply to violations of K.S.A. 2022 Supp. 21-5706 or 21-5713, and amendments thereto.
- (h) The sentence for a violation of K.S.A. 2022 Supp. 21-5703 or 21-5705, and amendments thereto, with respect to material containing any quantity of a fentanyl-related controlled substance shall be presumed imprisonment and shall be two times the maximum duration of the presumptive term of imprisonment. Such sentence shall not be considered a departure and shall not be subject to appeal.
- (i) The sentence for a violation of K.S.A. 2022 Supp. 21-5703 or 21-5705, and amendments thereto, shall be presumed imprisonment and shall be two times the maximum duration of the presumptive term of imprisonment if the trier of fact makes a finding beyond a reasonable doubt that the controlled substance involved, because of its appearance or packaging, was likely to be attractive to minors. Such sentence shall not be considered a departure and shall not be subject to appeal.
- 23 Sec. 5. K.S.A. 2022 Supp. 21-5701, 21-5701b, 21-5703, 21-5705 and 24 21-6805 are hereby repealed.
- Sec. 6. This act shall take effect and be in force from and after its publication in the statute book.